REFERENCES
- Motta M, Tincani A, Lojacono A, et al. Neonatal outcome in patients with rheumatic disease. Lupus. 2004;13:718–723.
- Ostensen M. Disease specific problems related to drug therapy in pregnancy. Lupus. 2004;13:746–750.
- Rabiah PK, Vitale AT, Rabiah PK, Vitale AT. Noninfectious uveitis and pregnancy. Am J Ophthalmol. 2003;136:91–98.
- Kump LI, Cervantes C, x00F, et al. Patterns of exacerbations of chronic non-infectious uveitis in pregnancy and puerperium. Ocul Immunol Inflamm. 2006;14:99–104.
- Chan CC, Reed GF, Kim Y, et al. A correlation of pregnancy term, disease activity, serum female hormones, and cytokines in uveitis. Br J Ophthalmol. 2004;88:1506–1509.
- Agarwal RK, Chan CC, Wiggert B, Caspi RR. Pregnancy ameliorates induction and expression of experimental autoimmune uveitis. J Immunol. 1999;162:2648–2654.
- Zhu WH, Lu CZ, Huang YM, Link H, Xiao BG. A putative mechanism on remission of multiple sclerosis during pregnancy: estrogen-induced indoleamine 2,3-dioxygenase by dendritic cells. Mult Scler. 2007;13:33–40.
- Keeling SO, Oswald AE, Keeling SO, Oswald AE. Pregnancy and rheumatic disease: "by the book" or "by the doc." Clin Rheumatol. 2009;28:1–9.
- Ostensen M. Treatment with immunosuppressive and disease modifying drugs during pregnancy and lactation. Am J Reprod Immunol. 1992;28:148–152.
- Temprano KK, Bandlamudi R, Moore TL, Temprano KK, Bandlamudi R, Moore TL. Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheumatism. 2005;35:112–121.
- Ostensen M, von Esebeck M, Villiger PM, Ostensen M, von Esebeck M, Villiger PM. Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease. J Rheumatol. 2007;34:1266–1269.
- Mersereau J, Dooley MA. Gonadal failure with cyclophosphamide therapy for lupus nephritis: advances in fertility preservation. Rheum Dis Clin North Am. 2010;36:99–108, viii.
- Ostensen M, Ramsey-Goldman R. Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options? Drug Safety. 1998;19:389–410.
- Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62:385–392.
- Skomsvoll JF, Ostensen M, Irgens LM, Baste V. Obstetrical and neonatal outcome in pregnant patients with rheumatic disease. Scand J Rheumatol Suppl. 1998;107:109–112.
- Fleischmann R, Iqbal I, Nandeshwar P, Quiceno A. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Drug Safety. 2002;25:173–197.
- Mogadam M, Dobbins WO 3rd., Korelitz BI, Ahmed SW. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology. 1981;80:72–76.
- Mogadam M, Korelitz BI, Ahmed SW, Dobbins WO 3rd., Baiocco PJ. The course of inflammatory bowel disease during pregnancy and postpartum. Am J Gastroenterol. 1981;75:265–269.
- Elliott AB, Chakravarty EF, Elliott AB, Chakravarty EF. Immunosuppressive medications during pregnancy and lactation in women with autoimmune diseases. Women's Health. 2010;6:431–440; quiz 41–42.
- Ostensen M, Orger F, Nelson JL, Schuhmacher A, Hebisch G, Villiger PM. Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post partum. Ann Rheumatic Dis. 2005;64:839–844.
- Jap A, Chee SP. Immunosuppressive therapy for ocular diseases. Curr Opin Ophthalmol. 2008;19:535–540.
- Grunnet E, Nyfors A, Hansen KB. Studies of human semen in topical corticosteroid-treated and in methotrexate-treated psoriatics. Dermatologica. 1977;154:78–84.
- Martinez Lopez JA, Loza E, Carmona L. Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). Clin Exp Rheumatol. 2009;27:678–684.
- Ostensen M, Hartmann H, Salvesen K. Low dose weekly methotrexate in early pregnancy: a case series and review of the literature. J Rheumatol. 2000;27:1872–1875.
- Bermas BL, Hill JA. Effects of immunosuppressive drugs during pregnancy. Arthritis Rheumatism. 1995;38:1722–1732.
- Janssen NM, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med. 2000;160:610–619.
- Ostensen M. Counselling women with rheumatic disease—how many children are desirable? Scand J Rheumatol. 1991;20:121–126.
- Buckley LM, Bullaboy CA, Leichtman L, Marquez M. Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheumatism. 1997;40:971–973.
- Kozlowski RD, Steinbrunner JV, MacKenzie AH, Clough JD, Wilke WS, Segal AM. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med. 1990;88:589–592.
- Mottet C, Juillerat P, Pittet V, et al. Pregnancy and breastfeeding in patients with Crohn's disease. Digestion. 2007;76:149–160.
- Feldkamp M, Carey JC. Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy. Teratology. 1993;47:533–539.
- Elliott AB, Chakravarty EF, Elliott AB, Chakravarty EF. Management of rheumatic diseases during pregnancy. Postgrad Med. 2010;122:213–221.
- Cao ZG, Liu JH, Zhu YP, et al. [Effects of different immunodepressants on the sperm parameters of kidney transplant recipients]. Zhonghua Nan Ke Xue. 2006;12:405–407.
- Ostensen M, Lockshin M, Doria A, et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford). 2008;47 (Suppl 3):iii28–31.
- Enns GM, Roeder E, Chan RT, Ali-Khan Catts Z, Cox VA, Golabi M. Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype? Am J Med Genet. 1999;86:237–241.
- le Gallez P. Teratogenesis and drugs for rheumatic disease. Nursing Times. 1988;84:41–44.
- Ostesen M. Optimisation of antirheumatic drug treatment in pregnancy. Clin Pharmacokinet. 1994;27:486–503.
- Steege JF, Caldwell DS. Renal agenesis after first trimester exposure to chlorambucil. South Med J. 1980;73:1414–1415.
- Liu L, Prasad SC, Bassano DA, Heavern J, Keshler B, Hahn SS. A dwell position verification method for high dose rate brachytherapy. J Appl Clin Med Phys. 2004;5:1–5.
- Botta JA Jr., Hawkins HC, Weikel JH Jr,. Effects of cyclophosphamide on fertility and general reproductive performance of rats. Toxicol Appl Pharmacol. 1974;27:602–611.
- Anchan RM, Ginsburg ES. Fertility concerns and preservation in younger women with breast cancer. Crit Rev Oncol Hematol. 2010;74:175–192.
- Wang CL, Wang F, Bosco JJ. Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus. 1995;4:11–14.
- Kainz A, Harabacz I, Cowlrick IS, Gadgil S, Hagiwara D. Analysis of 100 pregnancy outcomes in women treated systemically with tacrolimus. Transpl Int. 2000;13Suppl 1:S299–S300.
- Kainz A, Harabacz I, Cowlrick IS, Gadgil SD, Hagiwara D. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation. 2000;70:1718–1721.
- Deuter CM, Zierhut M, Mohle A, Vonthein R, Stobiger N, Kotter I. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behçet's disease. Arthritis Rheum. 2010;62:2796–2805.
- Kuemmerle-Deschner JB, Tzaribachev N, Deuter C, Zierhut M, Batra M, Koetter I. Interferon-alpha—a new therapeutic option in refractory juvenile Behçet's disease with CNS involvement. Rheumatology (Oxford). 2008;47:1051–1053.
- McGuire JL. The endocrine system and connective tissue disorders. Bull Rheum Dis. 1990;39:1–8.
- Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J. et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol. 2003;30:1277–1279.
- Huang JL, Hung IJ, Hsieh KH. Sulphasalazine therapy in chronic uveitis of children with chronic arthritis. Asian Pac J Allergy Immunol. 1997;15:71–75.
- Hoo JJ, Hadro TA, Von Behren P. Possible teratogenicity of sulfasalazine. N Engl J Med. 1988;318:1128.
- Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis. 2006;65:1631–1634.
- Simonini G, Cantarini L, Bresci C, Lorusso M, Galeazzi M, Cimaz R. Current therapeutic approaches to autoimmune chronic uveitis in children. Autoimmun Rev. 2010;9:674–683.
- Farvardin M, Afarid M, Mehryar M, Hosseini H. Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina. 2010;30:1530–1535.
- Ostensen M, Lockshin M, Doria A, et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford). 2008;47 (Suppl 3):iii28–31.
- Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol. 2006;4:1255–1258.
- Rosner I, Haddad A, Boulman N, et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford). 2007;46:1508; author reply -9.
- Chambers CD, Tutuncu ZN, Johnson D, Jones KL. Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data. Arthritis Res Ther. 2006;8:215.
- Onal S, Kazokoglu H, Koc A, Yavuz S. Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener's granulomatosis. Ocul Immunol Inflamm. 2008;16:230–232.
- Davatchi F, Shams H, Rezaipoor M, et al. Rituximab in intractable ocular lesions of Behçet's disease; randomized single-blind control study (pilot study). Int J Rheum Dis. 2010;13:246–252.
- Geissal ED, Wernick R. A case of severe MAGIC syndrome treated successfully with the tumor necrosis factor-alpha inhibitor infliximab. J Clin Rheumatol. 2010;16:185–187.
- Vinet E, Pineau C, Gordon C, Clarke AE, Bernatsky S. Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis Rheum. 2009;61:587–592.
- Beitins IZ, Bayard F, Ances IG, Kowarski A, Migeon CJ. The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr. 1972;81:936–945.
- Carmichael SL, Shaw GM. Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet. 1999;86:242–244.
- Lockshin MD, Sammaritano LR. Corticosteroids during pregnancy. Scand J Rheumatol Suppl. 1998;107:136–8.
- Rayburn WF. Glucocorticoid therapy for rheumatic diseases: maternal, fetal, and breast-feeding considerations. Am J Reprod Immunol. 1992;28:138–140.
- Sauk J, Kane S. The use of medications for inflammatory bowel disease during pregnancy and nursing. Expert Opin Pharmacother. 2005;6:1833–1839.
- Ost L, Wettrell G, Bjorkhem I, Rane A. Prednisolone excretion in human milk. J Pediatr. 1985;106:1008–1011.
- Needs CJ, Brooks PM. Antirheumatic medication during lactation. Br J Rheumatol. 1985;24:291–297.
- Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratology. 2002;65:240–261.
- Goldstein LH, Dolinsky G, Greenberg R, et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol. 2007;79:696–701.
- Norgard B, Pedersen L, Christensen LA, Sorensen HT. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol. 2007;102:1406–1413.
- Sau A, Clarke S, Bass J, Kaiser A, Marinaki A, Nelson-Piercy C. Azathioprine and breastfeeding: is it safe? BJOG. 2007;114:498–501.
- Armenti VT, Ahlswede KM, Ahlswede BA, Jarrell BE, Moritz MJ, Burke JF. National Transplantation Pregnancy Registry—outcomes of 154 pregnancies in cyclosporine-treated female kidney transplant recipients. Transplantation. 1994;57:502–506.
- Nyberg G, Haljamae U, Frisenette-Fich C, Wennergren M, Kjellmer I. Breast-feeding during treatment with cyclosporine. Transplantation. 1998;65:253–255.
- Cassoux N, Goichot-Bonnat L, Karmochkine M, et al. [Efficacy of intravenous immunoglobulin in the treatment of birdshot retinochoroiditis]. J Fr Ophtalmol. 2002;25:23–30.
- Onal S, Foster CS, Ahmed AR. Efficacy of intravenous immunoglobulin treatment in refractory uveitis. Ocul Immunol Inflamm. 2006;14:367–374.
- Stephenson MD, Kutteh WH, Purkiss S, et al. Intravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multicentered randomized placebo-controlled trial. Hum Reprod. 2010;25:2203–2209.
- Lazarus AH. Adoptive-transfer effects of intravenous immunoglobulin in autoimmunity. J Clin Immunol. 2010;30(Suppl 1):S20–S23.
- Friedman DM, Llanos C, Izmirly PM, et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum. 2010;62:1138–1146.
- Hemady RK, Chan AS, Nguyen AT. Immunosuppressive agents and nonsteroidal anti-inflammatory drugs for ocular immune and inflammatory disorders. Ophthalmol Clin North Am. 2005;18:511–528, vi.
- Levinson RD, Rosenbaum JT. Nonsteroidal anti-inflammatory drugs for prophylaxis of acute anterior uveitis. Ocul Immunol Inflamm. 2010;18:69–71.
- Stone S, Khamashta MA, Nelson-Piercy C. Nonsteroidal anti-inflammatory drugs and reversible female infertility: is there a link? Drug Safety. 2002;25:5455–5451.
- Dawood MY. Nonsteroidal antiinflammatory drugs and reproduction. Am J Obstet Gynecol. 1993;169:1255–1265.
- American Academy of Pediatrics Committee on Drugs: The transfer of drugs and other chemicals into human milk. Pediatrics. 1994;93:137–150.
- Treatment of rheumatoid arthritis: unknown long-term effects. Prescrire Int. 2001;10:55–61.
- Stutz G, Martini AC, Ruiz RD, Fiol De Cuneo M, Munoz L, Lacuara JL. Functional activity of mouse sperm was not affected by low doses of aspirin-like drugs. Arch Androl. 2000;44:117–128.